Targeting Prostate Cancer, the 'Tousled Way'
Source : https://pubmed.ncbi.nlm.nih.gov/37446279/
Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone...
Targeting TLK1 and its associated signaling could prevent PCa progression to the incurable metastatic castration-resistant PCa (mCRPC) stage and provide a promising approach to treating PCa.
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
Source : https://pubmed.ncbi.nlm.nih.gov/36935345/
Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) has become a standard imaging examination for prostate cancer. We propose a comprehensive framework for the analysis and reporting of PSMA-PET...
PROMISE V2 offers standardized reporting of disease extent for clinical routine and research. Parameters recorded within clinical trials facilitate objective response assessment.
Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach
Source : https://pubmed.ncbi.nlm.nih.gov/37738978/
Cancer immunotherapy has gained traction in recent years owing to remarkable tumor clearance in some patients. Despite the notable success of immune checkpoint blockade (ICB) in multiple malignancies, engagement of...
This review also focuses on emerging mechanism-based small-molecule tyrosine kinase inhibitors with immune modulatory properties that, either as single agents or in combination with other immunotherapies, have the potential to improve clinical outcomes.
Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers
Source : https://pubmed.ncbi.nlm.nih.gov/37628978/
Epidemiological data highlight prostate cancer as a significant global health issue, with high incidence and substantial impact on patients' quality of life. The prevalence of this disease is associated with...
Recent achievements in the identification of biomarkers provided by circulating monocytes and tumor-associated macrophages (TAMs). We highlight that monocyte-derived and TAM-derived biomarkers can enable to establish the missing links between genetic predisposition, hormonal metabolism and immune responses in prostate cancer.
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
Source : https://pubmed.ncbi.nlm.nih.gov/37068396/
Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of cancer-related death among men in the world. In addition,...
Understanding mechanisms of drug resistance in mCRPC is crucial for developing effective treatments. Strategies targeting taxanes, ARSIs, and PARP inhibitors are essential to improve therapeutic outcomes and overcome resistance challenges.